Section 174 & 174A · Brief · Pro level
Section 174 in consolidated groups: intercompany research, ownership of the deduction, and departing members
In a consolidated group, each member computes its own Section 174 and 174A items, but intercompany research arrangements decide which member holds the SRE cost — and the intercompany transaction regulations defer the seam. When a member leaves, its unamortized balances leave with it.
A consolidated return does not merge Section 174 into one pot. Each member computes its own items — including SRE expenditures — as a separate corporation first, and the consolidated return regulations then knit the results together. So the threshold question inside a group is the same one that governs strangers: which member's research is it? The answer follows financial risk and rights in results, exactly as in the reimbursed-research analysis, and intercompany cost-plus development agreements assign the SRE cost to the funding member, not the performing one. The consolidated regulations at Treas. Reg. §1.1502-13 (eCFR Title 26) then police the timing seam between the two.
Who owns the deduction inside the group
Groups centralize research for good reasons — one engineering entity, IP in a holding company, payroll in an employer entity — and every one of those structures splits the people from the risk and rights. The member with rights in the results and the economic exposure holds the SRE expenditures, measured by what it pays; the performing member paid on a no-risk, no-rights basis has deductible service costs. During TCJA-era capitalization this allocation decided which member's taxable income absorbed the hit, which mattered for state returns filed on a separate-company basis even when the federal consolidated answer washed. It still matters: domestic costs now deduct currently under Section 174A, but foreign research remains on 15-year amortization under Section 174, so a group with a foreign-branch development center must know which member carries that balance.
The intercompany transaction rules add the timing overlay. When the performing member charges a markup, §1.1502-13's matching rule redetermines the performer's income to keep the group where a single corporation would be — significant while the payer capitalizes and amortizes rather than deducting. The intercompany profit does not escape; it is deferred and matched against the payer's recovery.
Attributes, elections, and the group boundary
Method questions are member-level: each member has its own accounting methods, and a member changing 174 treatment files its own Form 3115 through the common parent as agent — the mechanics are covered in Section 481(a) and 174. Transition choices under the OBBBA (the one- or two-year catch-up for remaining 2022–2024 domestic balances) likewise run member by member, though a consistent group position is the practical norm. The small-business retroactive option is effectively a group-level test: Section 448(c) aggregation counts the whole group's receipts.
Capitalization-era 174 also fed the consolidated NOL. Where research members generated the disallowed deductions, the SRLY and attribute-allocation rules determine how much of the CNOL belongs to each member — which becomes real money when a member leaves.
Departing members
What a subsidiary carries out of the group at closing:
| Attribute | Travels with the departing member? |
|---|---|
| Unamortized 174 balances (foreign 15-year; unwinding 2022–2024 domestic) | Yes — its own schedules continue |
| Apportioned share of consolidated NOL (§1.1502-21) | Yes, as allocated |
| Deferred intercompany items under §1.1502-13 | No — generally accelerated into the group's income at deconsolidation |
| Accounting methods (174 treatment, allocation method) | Yes — subject to the new group's conformity |
The acceleration rule is the sleeper: intercompany research profit the group has been deferring springs into income when the parties cease to be members. And the buyer's diligence question is precise: which entity in the seller's group holds the amortization schedule, the IP, and the development agreement? A carve-out that buys the IP-owning member but not the employer entity — or the reverse — can leave the balance, or the workforce, behind. The broader checklist is in tax incentive due diligence in M&A.
Frequently asked questions
- Which member of a consolidated group deducts research performed by one member for another?
- The member that bears the financial risk of the research or holds rights in its results — the same risk-and-rights analysis that governs unrelated parties. A member performing research for a sister on a cost-plus basis with no retained rights has ordinary service costs; the funding member holds the SRE expenditures. The consolidated intercompany transaction rules of Treas. Reg. §1.1502-13 then match the performer's income with the payer's deduction or amortization timing.
- What happens to unamortized Section 174 balances when a subsidiary leaves a consolidated group?
- They travel with the subsidiary. Amortization schedules are attributes of the member that incurred the costs, so a departing member takes its remaining foreign 15-year balances and any unwinding 2022–2024 domestic amounts into its next return — separate, or in a new group. Buyers should confirm which member of the seller's group actually holds the balance before pricing it.
- Does consolidation change the Section 174A small-business gross receipts test?
- Effectively yes. The $31 million average-gross-receipts ceiling for retroactive Section 174A relief applies with the aggregation rules of Section 448(c), which treat a parent and its subsidiaries as one taxpayer. A small research subsidiary inside a large group cannot claim the small-business transition option on its own numbers.